APLS - Apellis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.17
-0.22 (-1.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close21.39
Open21.29
Bid0.00 x 800
Ask0.00 x 1200
Day's Range21.07 - 21.54
52 Week Range11.45 - 24.84
Volume152,323
Avg. Volume434,823
Market Cap1.339B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.78
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.80
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

    CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel.

  • GlobeNewswire11 days ago

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on May 20, 2019, the Compensation Committee of the Board of Directors approved the grant of an equity award, as of June 3, 2019, to a new employee as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee's acceptance of employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 36,404 shares of Apellis common stock.

  • Investors Who Bought Apellis Pharmaceuticals (NASDAQ:APLS) Shares A Year Ago Are Now Up 10%
    Simply Wall St.17 days ago

    Investors Who Bought Apellis Pharmaceuticals (NASDAQ:APLS) Shares A Year Ago Are Now Up 10%

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

  • Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)

    Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

  • GlobeNewswirelast month

    Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results

    Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals® Cash Position of $288.2 Million at.

  • Apellis executives got a raise 2018 and will get another in 2019
    American City Business Journals2 months ago

    Apellis executives got a raise 2018 and will get another in 2019

    Two Apellis Pharmaceuticals Inc. executives saw the value of their total compensation more than double in 2018 from the year before, according to a proxy filing from the company. Crestwood, Ky.-based Apellis (Nasdaq: APLS) cites several accomplishments, including progress on the company's clinical trials for its signature treatment, for the increases in compensation.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $17.00 per share, which includes 900,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less underwriting discounts and commissions. This offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The shares are being offered by Apellis pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”) on December 28, 2018 and amended on February 26, 2019.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. The shares are being offered by Apellis pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”) on December 28, 2018 and amended on February 26, 2019.

  • Apellis resumes trial after safety investigation
    American City Business Journals3 months ago

    Apellis resumes trial after safety investigation

    The clinical-stage biopharmaceutical company paused the Phase 3 clinical trial of its leading treatment candidate.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

    WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel.

  • GlobeNewswire3 months ago

    Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that with the agreement of the independent safety monitoring committee for the Company’s Phase 3 clinical program for APL-2 in patients with Geographic Atrophy (GA), the Company has resumed enrollment in its two Phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2. “Patient safety is our first priority and we feel that we can now reinitiate our Phase 3 program for patients with geographic atrophy with confidence following an in-depth investigation and modifications to the manufacturing process,” said Cedric Francois, CEO and co-founder of Apellis.

  • Apellis lands as much as $250M in financing from drug development company
    American City Business Journals4 months ago

    Apellis lands as much as $250M in financing from drug development company

    Apellis Pharmaceutical's newest deal will support clinical development for rare blood disorders.

  • GlobeNewswire4 months ago

    Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications

    WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development company backed by Blackstone Life Sciences and Abingworth. This collaboration marks the first time that SFJ Pharmaceuticals has partnered with a pre-revenue biopharma company. As part of this collaboration, SFJ and Apellis have entered into an agreement to support the development of APL-2 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • GlobeNewswire4 months ago

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully.

  • GlobeNewswire4 months ago

    Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s APL-2, a novel inhibitor of complement factor C3, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). APL-2 is currently being studied in a Phase 3 active comparator trial in patients with PNH who remain anemic despite treatment with eculizumab.

  • GlobeNewswire4 months ago

    Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic anemia (AIHA).

  • GlobeNewswire5 months ago

    Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Thomas Lackner as Senior Vice President, Head of Europe. Prior to joining Apellis, Thomas was responsible for developing the global commercial strategy and launch organization for Prothena Biosciences in Europe, for their first global launch in a hematologic rare disease (AL amyloidosis).